Strategic Account Director

15 most promising stocks under $100 to buy. Published on March 19, 2026 at 9:21 pm by maham fatima in hedge funds, news. Page 1 of 9 In this article, we will discuss the 15 most promising stocks under $100 to buy. On March 12, Roger Ferguson, former Fed Vice Chair, joined 'Closing Bell' on CNBC to discuss what to expect from the Federal Reserve next week. Ferguson shared his expectation for a pause in interest rate hikes, aligning with the CME FedWatch tool's current investor sentiment. He outlined three primary reasons for this view: the Fed's established wait-and-see stance, incoming data that has been important but not decisive, and a CPI report that met expectations. He described the labor market data as moving sideways, with recent reports showing conflicting signals of both strength and weakness, which reinforced the likelihood of the Fed remaining on the sidelines. When challenged on the potential for rising inflation due to a core CPI of 2.5% and an impending oil shock, Ferguson acknowledged that core PCE could be closer to 2.9% and that energy prices will likely cause a spike in headline inflation. He explained that Fed policymakers often view an oil spike as stagflationary; it simultaneously raises inflation temporarily and drains consumer liquidity, which can lead to economic stagnation. The critical determination for the Fed, according to Ferguson, is whether this inflation is a temporary reaction to an oil shock or if it begins to embed into long-term expectations, which would eventually force a tightening of monetary policy. Our methodology. We used screeners to identify stocks that are trading below $100 per share and had an average upside potential of at least 30%. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds. Note: All data was sourced on March 17. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here). 15. GeneDx Holdings Corp. (NASDAQ:WGS) $73.00 +3.27%. GeneDx Holdings Corp. (NASDAQ:WGS) is one of the most promising stocks under $100 to buy. On March 10, GeneDx and Zevra Therapeutics (NASDAQ:ZVRA) announced a new partnership to launch a sponsored genetic testing program for NPC (Niemann-Pick disease type C). This aims to expand access to GeneDx's ExomeDx test for patients in the US who are suspected of having this rare, inherited condition. By providing high-quality exome sequencing at no charge to eligible patients, the program seeks to help clinicians confirm diagnoses more quickly and guide informed clinical decision-making. The program addresses the challenges of NPC, which is a progressive neurodegenerative disorder caused by mutations in the NPC1 and NPC2 genes. Because the disease often presents with symptoms that overlap with other metabolic or neurological conditions, diagnosis is frequently delayed. This collaboration focuses on removing barriers to genomic testing, allowing healthcare providers to receive results in as little as 3 weeks. Identifying patients earlier is considered a critical step in managing the disease and ensuring access to appropriate therapies as they emerge. De-identified data from the testing program will be integrated into GeneDx Infinity, which is a large rare-disease genomic dataset. This integration is intended to help biopharmaceutical partners better understand disease biology and accelerate the journey from diagnosis to treatment. Zevra Therapeutics is providing financial support for the program, reflecting a joint commitment to using genomic insights to improve outcomes for individuals and families affected by NPC. GeneDx Holdings Corp. (NASDAQ:WGS) is a genomics company in the healthcare industry. It provides genetic testing services and provides pediatric & rare disease diagnostics. 14. Booz Allen Hamilton Holding Corporation (NYSE:BAH) $80.83 +2.76%. Booz Allen Hamilton Holding Corporation (NYSE:BAH) is one of the most promising stocks under $100 to buy. On March 11, Booz Allen Hamilton announced an investment in Hadean, which is a UK-based tech firm specializing in AI-powered digital wargaming and command and control capabilities. This move by Booz Allen Ventures marks the firm's first international investment and is designed to help Hadean establish a presence in the US. The collaboration builds on a two-year partnership aimed at modernizing military training and mission rehearsals for the US, NATO, and other Western allies through advanced synthetic environments. The partnership integrates Hadean's simulation platform with Booz Allen Hamilton Holding Corporation's (NYSE:BAH) role as a leading provider of AI to the federal government to deliver joint solutions involving agentic and spatial computing. These technologies are intended to revolutionize operational readiness by replacing legacy systems with scalable, secure, and deployable capabilities. While the primary focus remains on defense and the warfighter, the technology has potential applications across the civil, intelligence, and national security sectors to provide a decisive edge in complex environments. Booz Allen Hamilton Holding Corporation (NYSE:BAH) is a consulting services company that provides technology solutions using AI and cyber technologies for the government and commercial customers. Page 1 of 9 Related Insider Monkey Articles

GeneDx has partnered with Zevra Therapeutics to launch a genetic testing programme for patients with suspected Niemann-Pick disease type C (NPC), a rare inherited condition that causes progressive neurodegeneration. The programme will provide eligible US patients with free access to GeneDx's ExomeDx test, with results available in as little as three weeks. NPC is caused by mutations in the NPC1 and NPC2 genes, leading to abnormal lipid buildup in organs and the brain. The condition is frequently underdiagnosed due to clinical variability and symptom overlap with other neurological conditions. Zevra will provide financial support for the programme, whilst de-identified data will be added to GeneDx Infinity, the world's largest rare disease genomic dataset, to accelerate future diagnoses and inform treatment decisions.

GeneDx Holdings has raised investor interest following quarterly results showing 41% revenue growth in 2025 and earnings above estimates. The stock recently gained 7.45%, reaching $94.51, with a seven-day return of 27.37%. Despite recent momentum, longer-term performance remains mixed, with a one-year total shareholder return of 5.41% and a five-year decline of 84.08%. Analysts suggest the stock is 39.7% undervalued, with a narrative fair value of $156.67. The company is expanding into underpenetrated markets including general paediatrics, NICU and additional paediatric specialties, positioning itself as genomics adoption accelerates as a frontline diagnostic tool. However, the growth story faces risks from potential reimbursement pressures and slower-than-expected market expansion.